startups technology enabled weight loss services glp-1 These weight-loss tell customers they can stop taking Ozempic or Wegovy and stay thin. Doctors disagree GLP-1 Business Report for Healthtech

doi: 10.1136/bcr-2023-255319 [PubMed] 37519503 Doar NW, Adhikari S, Aryal B, Edara S, Schmidt M

#Pharmacology #NSAIDs #ClinicalPharmacy #PharmaceuticalScience #DrugMechanism #PharmacyStudents #MedicalEducation To view or add a comment, sign in 1,065 followers

The industry will no longer be limited to appetite suppressants and fat absorption inhibitors, as there are many promising oral GLP-1 receptor agonists, dual incretin agonists, triple agonists, and more to take on against the competition from injectables

This multi-pronged approach may be especially beneficial for patients who have not achieved satisfactory results with single-agent therapies